TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26715213
Drug: Efavirenz 400
Normalized name: efavirenz 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 400 mg (EFV400)
Study: 26715213
Drug: Efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 600 mg (EFV600)
Study: 21256786
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral hygiene with chlorhexidine (GS)
Study: 21256786
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral hygiene with electric dental brush (GR)
Study: 2915238
Drug: One-day cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day cisplatin, doxorubicin, and cyclophosphamide (PAC-I) chemotherapy
Study: 2915238
Drug: Five-day PAC
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day PAC (PAC-V) chemotherapy
Study: 27696678
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation for 15 minutes daily for 90 days
Study: 21808851
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg, 3 times/day)
Study: 15803287
Drug: Combined mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined mitoxantrone and methylprednisolone therapy
Study: 7549222
Drug: Zatebradine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zatebradine (10 mg)
Study: 9609523
Drug: Oral pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pamidronate 300 mg daily
Study: 7974588
Drug: CC method
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC method
Study: 29306223
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate intake
Study: 25616519
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (4 g/kg/d)
Study: 19469885
Drug: Magnesium carbonate/calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium carbonate/calcium carbonate (elemental Mg: 86 mg/elemental Ca 100 mg) administered as phosphate binder for 18 months
Study: 19469885
Drug: Magnesium carbonate/calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium carbonate/calcium carbonate (elemental Mg: 86 mg/elemental Ca 100 mg)
Study: 24923372
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg)
Study: 11679451
Drug: OGTT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: OGTT + F (75 g glucose + 7.5 g fructose)
Study: 7834919
Drug: Lactate-buffered hemofiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate-buffered hemofiltration (lactate concentration 34-44.5 mmol/l)
Study: 7834919
Drug: Type II
Normalized name: collagen type II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type II bicarbonate-buffered fluid (bicarbonate concentration 39.7 mmol/l)
Study: 7834919
Drug: Type I
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type I bicarbonate-buffered fluid (bicarbonate concentration 31.4 mmol/l)
Study: 7834919
Drug: Type II
Normalized name: collagen type II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type II bicarbonate fluid (bicarbonate concentration 39.7 mmol/l)
Study: 29544063
Drug: l-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine supplementation
Study: 16708408
Drug: Plantago ovata
Normalized name: Plantago ovata seed
DrugBank: Plantago ovata seed (DB14585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantago ovata (2 sachets daily of 3.26 g for 20 days)
Study: 10781391
Drug: Selenomethionine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenomethionine (50 microg of Se daily for 28 days)
Study: 10781391
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Sodium selenite and Selenomethionine)
Study: 8748408
Drug: Dextran 40-based
Normalized name: Dextran 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 40-based preservation solution (Dex-PS)
Study: 1407917
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg intravaginal PGE2 tablets
Study: 1407917
Drug: Placebo intravaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravaginal tablets (Control)
Study: 2996161
Drug: Both combinations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both combinations of antibiotics
Study: 31688579
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.1 mg/d) + 200 mg progesterone (12 d every 3 mo)
Study: 30571235
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive treatment (target systolic blood pressure <120 mm Hg)
Study: 30571235
Drug: Standard antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antihypertensive treatment (target systolic blood pressure <140 mm Hg)
Study: 30571235
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (intensive and standard)
Study: 9177952
Drug: Moclobemide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (both doses)
Study: 12145765
Drug: Glucose (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (75 g)
Study: 3518072
Drug: butorphanol 2
Normalized name: butorphanol 2 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: butorphanol 2 mg
Study: 26099
Drug: Dipotassium chlorazepate
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipotassium chlorazepate divided daily dose (5 + 5 + 10 mg)
Study: 23365149
Drug: Oral risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral risedronate (RIS)
Study: 23146820
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg synthetic oral THC
Study: 23146820
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg synthetic oral THC
Study: 21078841
Drug: Low-dose Sativex
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Sativex (5.4 mg THC and 5.0 mg CBD)
Study: 21078841
Drug: High-dose Sativex
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Sativex (16.2 mg THC and 15.0 mg CBD)
Study: 21078841
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral THC
Study: 19608695
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of rotigotine (1.2 mg over 12 hours)
Study: 19608695
Drug: Transdermal application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal application of rotigotine (4.5 mg via 10-cm² patch for 24 hours)
Study: 11099054
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy (metronidazole, amoxicillin, and omeprazole for 2 weeks) followed by placebo for 1 year
Study: 11099054
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy and long-term omeprazole
Study: 10430396
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy
Study: 3529362
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg, given twice daily for 2 days
Study: 3529362
Drug: Placebo, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given twice daily for 2 days
Study: 30563582
Drug: Long-term continuous
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term continuous antipsychotic treatment
Study: 30563582
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of antipsychotics
Study: 22071059
Drug: 10 L
Normalized name: PEG-10 LANOLIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 L of oxygen by nonrebreather mask during and for 2 hours after cesarean delivery
Study: 22071059
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L of oxygen by nasal cannula during cesarean delivery only (standard care)
Study: 9155286
Drug: Detailed psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detailed psychological preparation and support
Study: 9155286
Drug: Standard informal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard informal preparation
Study: 7960973
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment including a new 'opponens roll' maneuver and self-stretching
Study: 3068344
Drug: Captopril (12.5‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5‐50 mg twice a day)
Study: 28617807
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment failure
Study: 3674849
Drug: Aminoglycoside serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycoside serum levels, total aminoglycoside dose, duration of therapy, sex, peak temperature, presence of bacteremia, shock, liver cirrhosis, dehydration, previous otic pathology or renal failure, and development of renal toxicity
Study: 25182045
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy for 6 months
Study: 20022872
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow stem cells (BMSCs) administered into infarct-related artery (IRA) at 4-6 days after primary PCI
Study: 11800181
Drug: Self-control training
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-control training procedure with reinforcer immediacy competing with another influential dimension (e.g., RvI or QvI)
Study: 23043578
Drug: Postoperative conformal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative conformal radiotherapy to a dose of 60 Gray in 30 fractions with concurrent low-dose temozolomide
Study: 31056733
Drug: cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilostazol (200 mg/day)
Study: 21921460
Drug: aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin (81 mg/day)
Study: 8729587
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg/day and bezafibrate 400 mg/day
Study: 2658640
Drug: Ceftazidime 1
Normalized name: ceftazidime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 1 g
Study: 1816189
Drug: Ceftazidime 3
Normalized name: ceftazidime 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 3 g
Study: 10672977
Drug: labetalol 100
Normalized name: HCTZ 25/LABETALOL 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol 100 mg
Study: 7049710
Drug: chlorthalidone 10
Normalized name: chlorthalidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorthalidone 10 mg
Study: 31668592
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg orally once daily for 12 weeks
Study: 22166255
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care (n=40) with traditional DMARDs (no prednisone or biologics).
Study: 16306499
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of salbutamol and fluticasone
Study: 30585337
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 1200 mg plus 400 mg vitamin E
Study: 30585337
Drug: Placebo (starch)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch) plus 400 mg vitamin E
Study: 22880108
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aerobic and resistance exercise
Study: 19379588
Drug: CAG regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAG regimen (aclarubicin/Ara-C, G-CSF)
Study: 7802307
Drug: Clonidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (75 micrograms) and Morphine (0.5 mg)
Study: 7802307
Drug: Morphine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.5 mg)
Study: 7001044
Drug: Povidone-iodine gel
Normalized name: povidone-iodine gel 10 % Medicated Pad
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine gel
Study: 24548259
Drug: Sugar-sweetened beverages
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-sweetened beverages (SSB) consumption (100 g day(-1))
Study: 24548259
Drug: Substitution of
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitution of 100 g of SSB by 100 g of water or diet drink
Study: 17966760
Drug: Thyme-primrose combination
Normalized name: THYME
DrugBank: Thyme (DB10983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyme-primrose combination
Study: 17966760
Drug: Thyme-primrose combination
Normalized name: THYME
DrugBank: Thyme (DB10983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyme-primrose combination and Placebo
Study: 26012585
Drug: STEEP-b plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: STEEP-b plus treatment as usual (TAU)
Study: 7759676
Drug: Behavioral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral and cognitive-behavioral therapy methods
Study: 7759676
Drug: Specific, focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific, focused therapy methods
Study: 2539203
Drug: Efamol (evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efamol (evening primrose oil containing gamma-linolenic acid, with vitamin E as preservative) - 8 capsules per day
Study: 25757593
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d pure hesperidin supplement
Study: 23497761
Drug: Fentanyl Sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl Sublingual Spray (FSS) 400 μg
Study: 23497761
Drug: Intravenous Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Fentanyl Citrate 100 μg
Study: 9252801
Drug: Tolcapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (200 mg)
Study: 11593078
Drug: Dextroamphetamine sulfate,
Normalized name: Dextroamphetamine Sulfate, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine sulfate, sustained-release capsules (30 to 60 mg)
Study: 30180273
Drug: CaCO3 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaCO3 1200 mg/day with 10,000 IU vitamin D3/day
Study: 30180273
Drug: CaCO3 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaCO3 1200 mg/day with 600 IU vitamin D3/day
Study: 26654135
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron (n = 85)
Study: 19150495
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil containing 3.7 g/day n‐3 polyunsaturated fatty acid (n‐3PUFA)
Study: 19150495
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil containing 3.7 g/day n‐3PUFA
Study: 8207699
Drug: Sandimmune Neoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune Neoral (180 mg)
Study: 2914336
Drug: 3 ml.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml.kg‐1 of apple juice given 2.6 +/‐ 0.4 hours preoperatively
Study: 31575326
Drug: Tropisetron (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (5 mg twice daily) and fluvoxamine (100 mg daily initially followed by 200 mg daily after week 4)
Study: 31575326
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and fluvoxamine (100 mg daily initially followed by 200 mg daily after week 4)
Study: 27929709
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal system (BTDS) and active controls (oxycodone/acetaminophen [OXY/APAP] and hydrocodone/acetaminophen [HCD/APAP])
Study: 18831530
Drug: Istradefylline 20
Normalized name: istradefylline 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istradefylline 20 mg once daily
Study: 11205194
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily for 4 months
Study: 7821060
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation therapy (5 fractions of 2 Gy each)
Study: 7821060
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation therapy (10 fractions of 2 Gy each)
Study: 8511308
Drug: Nonsteroidal antiinflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal antiinflammatory drug (NSAID) use
Study: 8511308
Drug: High RT
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High RT dose with short duration (< or = 9 days)
Study: 22672081
Drug: LM25 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LM25 therapy (25% insulin lispro, 75% insulin lispro protamine suspension)
Study: 22672081
Drug: Glargine +
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glargine + insulin lispro therapy
Study: 18772509
Drug: Simvastatin combined
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin combined with routine treatment (beta receptor blocker, calcium-channel blocker, long active nitrate)
Study: 18772509
Drug: Simvastatin combined
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin combined with routine treatment
Study: 18772509
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (beta receptor blocker, calcium-channel blocker, long active nitrate)
Study: 15970103
Drug: Verapamil-procaine compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil-procaine compound (V-P)
Study: 12575474
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg S-adenosyl-L-methionine (SAMe) administered intravenously
Study: 10597810
Drug: Bilateral injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral injections of 2% lidocaine solution without epinephrine into the paraglottic space containing the ibSLN
Study: 273801
Drug: ALICE live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALICE live virus intra-nasal vaccine
Study: 31387390
Drug: Dog-assisted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dog-assisted therapy intervention (50-min session per week for 9 months)
Study: 27696447
Drug: INCS daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCS daily (fluticasone propionate)
Study: 3314613
Drug: Oral diltiazem
Normalized name: diltiazem Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diltiazem 120 to 180 mg
Study: 29516704
Drug: 0.5 mcg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mcg/kg/h dexmedetomidine in addition to half dose of opioids and benzodiazepines (D-CASEs)
Study: 29516704
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose opioids and benzodiazepines (CONTROLs)
Study: 20859892
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration with isotonic solution (0.9% NaCl)
Study: 20859892
Drug: Oral hydration
Normalized name: terpin hydrate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydration with mineral water
Study: 12844139
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg) administered subcutaneously to subjects with severely impaired renal function
Study: 12844139
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg) administered subcutaneously to subjects with end-stage renal disease
Study: 8595479
Drug: Physostigmine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine infusion
Study: 10899358
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion of saline
Study: 8667466
Drug: Short infusion
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short infusion regimen of pralidoxime (4 mg/kg over 15 minutes followed by 3.2 mg/kg/h for 3.75 h)
Study: 8280545
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine 0.2 mg
Study: 20186889
Drug: TEP (totally
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEP (totally extraperitoneal patch)
Study: 11594447
Drug: Reboxetine 4
Normalized name: reboxetine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 4 mg twice daily for 14 days
Study: 11157143
Drug: IL‐1Ra 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1Ra 150 mg/day
Study: 16777649
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy (CST)
Study: 22914584
Drug: Primary immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary immunization with recombinant hepatitis B vaccine (Group 1, 5 years post-vaccination)
Study: 20683930
Drug: Colesevelam (1875
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (1875 mg twice daily for 3 weeks)
Study: 20683930
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical to colesevelam, twice daily for 3 weeks)
Study: 18000709
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg/kg plus dexamethasone 8 mg
Study: 18000709
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg/kg combined with dexamethasone 8 mg